KLRA Latest Press Releases

-- October 1, 2026 --

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting Globe Newswire 6:45 AM

-- September 30, 2026 --

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection Globe Newswire 7:00 AM

-- September 16, 2026 --

Kailera Therapeutics to Participate in September Investor Conferences Globe Newswire 7:00 AM

-- August 12, 2026 --

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 4:05 PM

-- August 11, 2026 --

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer Globe Newswire 7:00 AM

-- July 7, 2026 --

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 Globe Newswire 7:00 AM

-- June 29, 2026 --

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer Globe Newswire 7:30 AM

-- June 5, 2026 --

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 Globe Newswire 7:32 PM

-- May 28, 2026 --

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference Globe Newswire 4:05 PM

-- May 26, 2026 --

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates Globe Newswire 4:02 PM

Market Data Delayed 15 Minutes